
BIO
USDBio-Rad Laboratories Inc. Class A Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$309.870
उच्च
$316.200
कम
$301.920
मात्रा
0.18M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
8.3B
उद्योग
चिकित्सा उपकरण
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
0.24M
एक्सचेंज
NYQ
मुद्रा
USD
52-सप्ताह रेंज
AI विश्लेषण रिपोर्ट
अंतिम अपडेट: 1 नव॰ 2025BIO Stock Alert: Bio-Rad Laboratories Shows Short-Term Opportunity Amid Volatility
Breaking Down the Current Picture
Bio-Rad Laboratories (BIO) just wrapped up a wild October. The stock surged from $280 to $340 in three weeks, then crashed 6% in a single day after earnings. Today it’s sitting at $319.55--down from its October peak but still 5% above where it started the month. Let’s cut through the noise.
What the News Tells Us
- Analyst split is real: Citigroup doubled down with a $375 target (22% upside), while Wells Fargo stayed cautious at $340 despite raising their forecast.
- Earnings disappointment: The October 29 report triggered immediate selling. No details were provided in the data, but the timing aligns with BIO’s sharp 6% drop that day.
- Sentiment is neutral overall--bullish upgrades are fighting against weak fundamentals.
Price Action Decoded
Here’s what the chart whispers:
- The $340 wall matters: BIO tested this level twice in late October (Oct 21 and 24) but couldn’t break through. Each time, heavy selling followed.
- Support at $318.50 is make-or-break: Yesterday’s close ($319.55) barely held above this technical floor. Volume spiked to 510K shares on the drop (Oct 29)--more than double its average.
- That "bullish" MACD crossover? It happened at $322 on Oct 15, but the stock stalled anyway. Technicals alone won’t drive this move.
Where It’s Headed Next
Short-term signals are messy: ✅ Bullish spark: Current price hovering at the Bollinger Band lower limit ($318.51) often triggers bounces. ⚠️ Red flags: Negative ROE (-9.5%) and sky-high debt (20.7 D/E ratio) scream "fundamental trouble." 🔮 AI’s mixed forecast: +0.5% tomorrow → -0.3% the next day → +0.9% on day 3. Translation: Choppy trading ahead.
Actionable Guidance
For traders only--this isn’t a long-term hold.
Entry Strategy
- Best window: $317-$319.50 (yesterday’s low was $315.10--don’t chase below that).
- Why now?: Extreme volume on the drop (510K shares) suggests panic selling washed out.
- Critical trigger: Wait for a 15-minute candle closing above $322 to confirm reversal.
Exit Plan
- Take profit: $342 (Wells Fargo’s target). Anything beyond $345 faces serious resistance.
- Stop loss: $314.50 (1.5% below yesterday’s low). Do not move this lower.
- Time limit: Max 10 trading days. This setup dies if the $318 support breaks.
Who Should Skip This
- Long-term investors: Debt and negative ROE are structural issues.
- Risk-averse traders: The 6% single-day swing shows BIO isn’t for the faint of heart.
- Anyone needing stability: This stock moves on earnings whispers and analyst notes--not steady growth.
Bottom Line
BIO is a short-term scalp, not a portfolio cornerstone. The $318 support level is the fulcrum. If it holds with volume
संबंधित समाचार
Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories with a Buy and raises the price target from $350 to $375.
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories with a Equal-Weight and raises the price target from $265 to $340.
Bio-Rad Reports Third-Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. "During the third
AI भविष्यवाणीBeta
AI सिफारिश
पर अपडेट किया गया: 5 नव॰ 2025, 03:27 am
66.2% आत्मविश्वास
जोखिम और ट्रेडिंग
प्रवेश बिंदु
$308.48
लाभ लें
$317.74
स्टॉप लॉस
$280.36
मुख्य कारक
संबंधित स्टॉक
PGZ
Principal Real Estate Income Fund Common Shares of Beneficial Interest
ORGS
Orgenesis Inc.
AMED
Amedisys Inc
KNSA
Kiniksa Pharmaceuticals International plc Ordinary Shares
ARMN
Aris Mining Corporation Common Shares
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।